Overview of novel restore and target treatment approach to classical Hodgkin lymphoma
Novel lymphoma targets and agents
Andrew Zelenetz et al.
'Chemo-free' in follicular lymphoma
What’s next for inotuzumab ozogamicin in ALL?
Myeloma XI trial: impact of MRD on treatment response in MM